About this item:

698 Views | 669 Downloads

Author Notes:

To whom correspondence should be addressed: Beau B. Bruce, M.D., Ph.D. [E-mail: bbbruce@emory.edu]

The authors report no conflict of interest.

Subjects:

Research Funding:

This work was supported in part by an unrestricted departmental grant (Department of Ophthalmology) from Research to Prevent Blindness, Inc., New York and by National Institutes of Health/National Eye Institute (NIH/NEI) core grant P30-EY006360 (both to the Department of Ophthalmology, Emory University School of Medicine).

Dr. Hage received research grants from the Philippe Foundation (NYC, USA), the “Club de Neuro-Ophtalmologie Francophone” (Paris, France) and the “Faculté de Médecine des Antilles et de la Guyane” (bourse année-recherche).

Dr. Bruce receives research support form the NIH/NEI (K23-EY019341).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Clinical Neurology
  • Surgery
  • Neurosciences & Neurology
  • Cranial nerve palsy
  • Diplopia
  • Pituitary adenoma
  • Pituitary apoplexy
  • TRANSSPHENOIDAL SURGERY
  • CLINICAL-FEATURES
  • MANAGEMENT
  • HEMORRHAGE
  • ADENOMAS
  • SERIES
  • TUMORS
  • EXPERIENCE
  • OUTCOMES

Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Apoplexy

Tools:

Journal Title:

World Neurosurgery

Volume:

Volume 94

Publisher:

, Pages 447-452

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background Pituitary apoplexy (PA) often presents with acute headache and neuro-ophthalmic manifestations, including ocular motility dysfunction (OMD) from cranial nerve palsies (CNPs). Our goal was to describe the epidemiology and outcomes of OMD in a large, single-center series of patients with PA. Methods We conducted a retrospective chart review of all patients with PA seen in our pituitary center between January 1995 and December 2012. Presenting neuro-ophthalmic, endocrine, and radiologic data, as well as neuro-ophthalmology follow-up data, were collected. Results We identified 235 patients with PA, 59 of whom (25%) had OMD. Twenty-seven of those 59 patients underwent neuro-ophthalmic evaluation. Preoperatively, 23 of these 27 patients had unilateral OMD, 18 (78%) with a single CNP and 5 (22%) with multiple CNPs. Bilateral OMD was present in 4 of the 27 patients. Postoperatively, 24 of the 27 patients with OMD had follow-up (median duration, 7 months; interquartile range [IQR], 3–17 months). At the last postoperative follow-up, 7 of these 24 patients (29%) had OMD (5 unilateral, 2 bilateral). OMD resolved in 3 of the 24 patients (12%) within 1 month, in 13 of 21 patients (62%) within 6 months (3 lost to follow-up), and in 17 of 19 patients (89%) within 1 year (2 lost to follow-up). Surgery was performed at ≤14 days after presentation in 16 of 18 (89%) resolved cases and in 4 of 6 (67%) unresolved cases. Patients with OMD were more likely than those without OMD to have larger tumors (2.6 vs. 2.0 cm; P < 0.001), panhypopituitarism (31% vs. 14%; P = 0.005), and necrosis (58% vs. 37%; P = 0.03). Conclusions OMD from CNPs is common in PA, occurring in one-quarter of patients, and is frequently associated with certain radiologic, endocrinologic, and pathological features. The prognosis is excellent, with 90% of cases of OMD resolving by 1 year after early pituitary surgery.

Copyright information:

© 2016 Elsevier Inc.

Export to EndNote